替雷利珠单抗对比多西他赛治疗既往经治的晚期非小细胞肺癌患者(RATIONALE-303):一项3期、开放标签、随机对照试验
3期RATIONALE-303试验将805例既往经治的晚期非小细胞肺癌患者按2:1随机分配接受替雷利珠单抗200 mg或多西他赛75 mg/m²静脉给药、每3周一次。预设中期分析时,意向治疗人群总生存期达到共同主要终点(中位17.2 vs 11.9个月,HR=0.64,p<0.0001);最终分析时,PD-L1肿瘤细胞表达≥25%人群总生存期也达到共同主要终点(中位19.3 vs 11.5个月,HR=0.53,p<0.0001),意向治疗人群总生存期持续改善(中位16.9 vs 11.9个月,HR=0.66)。探索性生物标志物分析提示NOTCH1-4突变可能与替雷利珠单抗疗效改善相关,未发现新的安全性信号。
要点
- 意向治疗人群总生存期:替雷利珠单抗组中位17.2个月 vs 多西他赛组11.9个月(HR=0.64,p<0.0001)。
- PD-L1肿瘤细胞表达≥25%人群总生存期:替雷利珠单抗组中位19.3个月 vs 多西他赛组11.5个月(HR=0.53,p<0.0001)。
- 探索性分析提示NOTCH1-4突变可能与替雷利珠单抗总生存期和无进展生存期疗效改善相关。
核心结论
- 在既往经治的晚期非小细胞肺癌患者中,替雷利珠单抗对比多西他赛显著改善总生存期,且具有长期临床获益,无论PD-L1表达状态如何。
研究设计与样本
- 3期、开放标签、随机对照试验(RATIONALE-303,NCT03358875),共纳入805例年龄≥18岁的局部晚期或转移性鳞状或非鳞状非小细胞肺癌患者。
- 患者按2:1随机分配接受静脉替雷利珠单抗200 mg或多西他赛75 mg/m²,每3周一次。
- 共同主要终点为意向治疗人群和PD-L1肿瘤细胞表达≥25%人群的总生存期;探索性生物标志物分析包括PD-L1表达、肿瘤突变负荷和基因表达谱。
主要发现
- 预设中期分析(2020年8月10日)时,意向治疗人群总生存期达到共同主要终点:替雷利珠单抗组中位17.2个月 vs 多西他赛组11.9个月(HR=0.64,p<0.0001)。
- 最终分析(2021年7月15日)时,PD-L1肿瘤细胞表达≥25%人群总生存期达到另一共同主要终点:替雷利珠单抗组中位19.3个月 vs 多西他赛组11.5个月(HR=0.53,p<0.0001)。
- 最终分析时意向治疗人群总生存期持续改善:替雷利珠单抗组中位16.9个月 vs 多西他赛组11.9个月(HR=0.66)。
- 探索性生物标志物分析显示NOTCH1-4突变可能与替雷利珠单抗总生存期和无进展生存期疗效改善相关,组织肿瘤突变负荷与无进展生存期获益相关、但与总生存期获益不相关。
- 未发现新的安全性信号。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The phase 3 RATIONALE-303 trial (NCT03358875) investigated the efficacy and safety of tislelizumab versus docetaxel in pretreated patients with advanced NSCLC. Here, we report the efficacy and safety results and describe the exploratory biomarker analyses. METHODS: A total of 805 patients aged more than or equal to 18 years with locally advanced or metastatic squamous or nonsquamous NSCLC were randomized 2:1 to intravenous tislelizumab 200 mg or docetaxel 75 mg/m2 every 3 weeks. Co-primary end points were overall survival (OS) in the intent-to-treat (ITT) and programmed death-ligand 1 (PD-L1) tumor cell expression greater than or equal to 25% populations. The exploratory biomarker analyses included PD-L1 expression, tumor mutation burden, and gene expression profile. RESULTS: At the prespecified interim analysis (August 10, 2020), the co-primary end point of OS in the ITT population was met, with a statistically significant and clinically meaningful improvement in OS with tislelizumab versus docetaxel (median 17.2 versus 11.9 mo, respectively; hazard ratio [HR] = 0.64, p < 0.0001). At the final analysis (July 15, 2021), the other co-primary end point of OS in the PD-L1 tumor cell greater than or equal to 25% population was further met (median 19.3 versus 11.5 mo, respectively; HR = 0.53, p < 0.0001), and OS continued to improve in the ITT population (median 16.9 versus 11.9 mo, respectively, HR = 0.66). Exploratory biomarker analyses revealed the potential association of NOTCH1-4 mutations with improved tislelizumab efficacy for both OS and progression-free survival, whereas tissue tumor mutation burden correlated with progression-free survival benefit, but not OS benefit. No new safety signals were identified. CONCLUSIONS: Tislelizumab was found to have a significantly improved and long-term clinical benefit in OS versus docetaxel in pretreated patients with advanced NSCLC, regardless of PD-L1 expression.
引用
- Zhou C, Huang D, Fan Y, et al. Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial. J Thorac Oncol. 2022. PMID: 36184068. doi:10.1016/j.jtho.2022.09.217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。